Research paperSynthesis and SAR of Imidazo[1,5-a]pyridine derivatives as 5-HT4 receptor partial agonists for the treatment of cognitive disorders associated with Alzheimer's disease

Add time:08/30/2019    Source:sciencedirect.com

Alzheimer's disease (AD) is a neurodegenerative disease which has a higher prevalence and incidence in older people. The need for improved AD therapies is unmet. The 5-hydroxytryptamine4 receptor (5-HT4R) partial agonists may be of benefit for both the symptomatic and disease-modifying treatment of cognitive disorders associated with AD. Herein, we report the design, synthesis and SAR of imidazo[1,5-a] pyridine derivatives as 5-HT4R partial agonists. The focused SAR, optimization of ADME properties resulted the discovery of compound 5a as potent, selective, brain penetrant 5-HT4 partial agonist as a lead compound with good ADME properties and efficacy in both symptomatic and disease modifying animal models of cognition.

We also recommend Trading Suppliers and Manufacturers of 4-(BOC-AMINOMETHYL)PYRIDINE (cas 111080-65-0). Pls Click Website Link as below: cas 111080-65-0 suppliers

Prev:A convergent route to substituted azetidines and to Boc-protected 4-aminomethylpyrroles
Next:Chapter 5.1 - Six-Membered Ring Systems: Pyridine Benzo Derivatives)